Biologics by McKesson Expands Specialty Pharmacy Capabilities to Serve Patients with Rare and Complex Conditions
Exclusive distribution agreement for rare disease therapy strengthens the specialty pharmacy’s footprint beyond oncology…
Biologics, Inc. Joins MedImpact Direct Specialty Program’s Specialty Pharmacy Network: Innovative Hub Conducts Prescription-Level Utilization Management
Biologics by McKesson joined the MedImpact Direct Specialty program to dispense specialty prescriptions through a hub model that supports plan-specific utilization management and coordination between prescribers and the fulfillment pharmacy.
Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy
Biologics earned URAC Specialty Pharmacy accreditation, recognizing the organization’s adherence to rigorous quality and safety standards and its commitment to patient-centered care and process improvement.
BAVENCIO® (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.
Biologics was selected as a specialty pharmacy provider for BAVENCIO, the first FDA-approved treatment for adults and certain pediatric patients with metastatic Merkel cell carcinoma.
Biologics, Inc. Announces New Oncology Partnership
Biologics was selected as the exclusive specialty pharmacy provider for VARUBI, approved with other antiemetics to help prevent delayed nausea and vomiting from emetogenic cancer chemotherapy.
PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.
Biologics was selected as the exclusive specialty pharmacy provider for PORTRAZZA, approved with gemcitabine and cisplatin for first-line treatment of metastatic squamous non-small cell lung cancer.
Ibrance® (palbociclib) approved for ER+, HER2- advanced breast cancer, available immediately at Biologics, Inc.
Biologics was selected as a specialty pharmacy authorized to dispense Ibrance, approved with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer.
Jakafi® (ruxolitinib) approved for new indication, available at Biologics
Biologics announced the FDA’s new Jakafi indication for patients with polycythemia vera who are intolerant of or inadequately responsive to hydroxyurea.